  The novel coronavirus SARS-CoV-2 has resulted in a global pandemic with
worldwide 6-digital infection rates and thousands death tolls daily. Enormeous
effords are undertaken to achieve high coverage of immunization in order to
reach herd immunity to stop spreading of SARS-CoV-2 infection. Several
SARS-CoV-2 vaccines, based either on mRNA, viral vectors, or inactivated
SARS-CoV-2 virus have been approved and are being applied worldwide. However,
recently increased numbers of normally very rare types of thromboses associated
with thrombocytopenia have been reported in particular in the context of the
adenoviral vector vaccine ChAdOx1 nCoV-19 from Astra Zeneca. While statistical
prevalence of these side effects seem to correlate with this particular vaccine
type, i.e. adenonoviral vector based vaccines, the exact molecular mechanisms
are still not clear. The present review summarizes current data and hypotheses
for molecular and cellular mechanisms into one integrated hypothesis indicating
that coagulopathies, including thromboses, thrombocytopenia and other related
side effects are correlated to an interplay of the two components in the
vaccine, i.e. the spike antigen and the adenoviral vector, with the innate and
immune system which under certain circumstances can imitate the picture of a
limited COVID-19 pathological picture.
